Key result
100% dalteparin linked to ~166% greater odds of adequate anti-Xa levels vs 75% in renal impairment.
Why the study?
Guidelines recommend a 25-50% dalteparin dose reduction with anti-Xa monitoring in renally impaired patients, but pharmacokinetic data and prior studies question this need.
Does a 100% dalteparin dose improve the achievement of adequate anti-Xa levels compared to a 75% dose in renally impaired patients?
Observational
Yes
Does a 100% dalteparin dose improve the achievement of adequate anti-Xa levels compared to a 75% dose in renally impaired patients?
In renally impaired patients, a 100% dalteparin dose increases the likelihood of achieving adequate anti-Xa levels compared with a 75% dose without leading to over-exposure or increased bleeding, suggesting pre-emptive dose reduction may be unnecessary.
May support full-dose dalteparin to meet anti-Xa targets in renal impairment; leaves open clinical outcomes and requires RCT confirmation.
BACKGROUND: In renally impaired patients, guidelines recommend a 25-50% dalteparin dose reduction with anti-Xa monitoring to reduce bleeding risk. However, pharmacokinetic considerations and results from previous studies dispute the need for dose reduction. Therefore, in our hospitals an alternative dose reduction to 75% or a 100% is used. This study aimed to assess anti-Xa levels to confirm or refute the need for dose reduction and to investigate the association between dose, anti-Xa levels and bleeding events. METHODS: or on renal replacement therapy, receiving ≥7500 IU dalteparin daily. Only correctly sampled plasma anti-Xa levels were included and stratified into intensive care unit (ICU) and non-ICU patients. Stratum-adjusted odds ratios were determined to compare the likelihood of achieving adequate anti-Xa levels between a 75% and 100% dose. Bleeding events were classified into minor and major events. RESULTS: A total of 167 anti-Xa levels were included, with 148 anti-Xa levels belonging to patients receiving a 75% or 100% dose. Anti-Xa levels were highly scattered: 55% below and 6% above the anti-Xa ranges. In all patients the probability that anti-Xa levels fell within the range was higher for patients receiving a 100% dose than for those receiving a 75% dose (OR 2.66, 95% CI 1.24 to 5.70, p=0.012). Eight bleeding events occurred, including one minor event in a patient with an anti-Xa level above range and five events in patients on renal replacement therapy with anti-Xa levels within or below range. CONCLUSIONS: In renally impaired patients a 100% dalteparin dose increases the likelihood of achieving adequate anti-Xa levels compared with a 75% dose, without leading to over-exposure. The occurrence of bleeding events did not differ between the 75% and 100% dose groups and appeared unrelated to anti-Xa levels. Pre-emptive dose reduction of dalteparin in renally impaired patients is likely to be unnecessary.
No takes yet. Share an insight, caveat, or question.
Pires et al. (2025) conducted an observational in Renal impairment. 100% dalteparin dose vs. 75% dalteparin dose was evaluated on Likelihood of achieving adequate anti-Xa levels (OR 2.66, 95% CI 1.24-5.70, p=0.012). A 100% dalteparin dose increased the likelihood of achieving adequate anti-Xa levels compared with a 75% dose in renally impaired patients (OR 2.66; 95% CI 1.24-5.70; p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: